Strictly a guess, just in case someone on here didn't realize that. (wink) :)
If the results show positive reversal of RD while not negating the pain killing drugs already administered, then I would look for a price eventually reaching the $3.50 range. Not the first day, nor the first week. But before a partnership announcement is made.
Then, again depending on the details of a partnership, another jump. Assuming a reasonable deal, I would expect to see $5 plus by the end of the year.
It will take some of the "show me the money" results to see this stock price grow. It just has beaten up too many investors. And with the general market black and blue from being buffeted, people will wait for more of a sure thing. Preservation of cash is now the order of the day.
However, a good showing will be rewarded.
This also, is just a guess on my part, but the lengthy delay we are seeing on RD#1 could very possibly be because they had to retest subjects due to the vry same things they saw on RD#2. I'd rather have this delay and good information from the trial, then no delay and bad results due to things other than our molecules. I think Cortex knows that it can't have these results look shoddy like RD#2 results appeared.
Cordially,
RBlatch
News 
Market Data 
Discover 
AI
